PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 74904

Title: EBV-Associated Smooth Muscle Tumors In Immunocompromised Patients – A Case Series

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05097961

Position: Peer Reviewer

Academic degree:

Professional title:

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: United States

Manuscript submission date: 2022-01-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-17 09:06

Reviewer performed review: 2022-03-04 02:07

Review time: 14 Days and 17 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ √ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ √ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ ] Yes | [ √ ] No |


SPECIFIC COMMENTS TO AUTHORS
This article reported rare case series of EBV-associated smooth muscle tumor in immunocompromised patients. The reported characteristics of their clinical course would be essential for future therapy. However, I have some comments as follows.

Minor revise: 1. In case 1, what was the size of polypoid lesions in the sigmoid colon and rectum, respectively? It would be better if endoscopic pictures are added to Figure 1 and 2. 2. In case 2, the authors reported that the patient had a history of “CD5 positive B-cell immune deficiency”. They need to check out the name of disease. Is there a possibility of CD5-positive diffuse large B-cell lymphoma? 3. In page 7 line 15, Figure 3a→3A 4. Regarding Figure1, 2, 4, 5, 6, 7, 8, and 9, corresponding Figure number should be included in the manuscript.
# PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology  
**Manuscript NO:** 74904  
**Title:** EBV-Associated Smooth Muscle Tumors In Immunocompromised Patients – A Case Series  
**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer's code:** 05426937  
**Position:** Peer Reviewer  
**Academic degree:** MD  
**Professional title:** Doctor  
**Reviewer's Country/Territory:** China  
**Author's Country/Territory:** United States  
**Manuscript submission date:** 2022-01-12  
**Reviewer chosen by:** Jia-Qi Zhu (Online Science Editor)  
**Reviewer accepted review:** 2022-03-10 06:42  
**Reviewer performed review:** 2022-03-17 03:27  
**Review time:** 6 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EBV-SMTs is a rare oncological entity found in immunocompromised patients with either primary immunodeficiency as in Congenital Immunodeficiency or secondary immunodeficiency as seen in patients with HIV or post-transplant patients on long term immunosuppression. As the number of transplant patients go up, these tumors are increasingly reported with the help of histopathology. There is no clear consensus on the treatment of EBV-SMTs. The manuscript provides a comprehensive, systematic and in-depth summary of that, including surgical resection, chemotherapy, radiation, and reduction of immunosuppression have been explored on a case-by-case basis with varying degrees of success. The median latency time between immunosuppression and disease diagnosis is four years. EBV-SMTs present with variable degree of aggressiveness and seem to have worse clinical outcomes in patients with tumor multiplicity and worse immunocompetency. Questions regarding best treatment modality remain as cases are treated on a case by case basis. It is imperative to continue building on this knowledge and keeping EBV-SMTs on the differential in immunocompromised individuals. In this manuscript case series explored six different cases of EBV-SMTs across different age groups, different types of EBV-SMTs, with different treatment modalities used and added to the limited existing knowledge on this rare type of tumors. Therefore, I recommend publishing this manuscript.